Dr Reddy Laboratories : . Reddy’s Q3 FY20 Financial Results

Press Release

			CONTACT
DR. REDDY'S LABORATORIES LTD.		INVESTOR RELATIONS			MEDIA RELATIONS
8-2-337, Road No. 3, Banjara Hills,		AMIT AGARWAL			DEEP GHATAK
Hyderabad - 500034. Telangana, India.
	[e-mail]			[e-mail]
		(Ph: [phone])			(Ph: [phone])

Dr. Reddy's Q3 & 9M FY20 Financial Results

Hyderabad, India, January 27, 2020:Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended December 31, 2019 under International Financial Reporting Standards (IFRS).

Q3 Performance Summary9M Performance Summary

`4,384 Cr	`13,028 Cr
Revenue	Revenue
[Down: 9% QoQ; Up: 14% YoY]	[Up: 15% YoY]
54.1%	54.7%
Gross Margin	Gross Margin
[Q2 FY20: 57.5%; Q3 FY19: 53.9%]	[9M FY19: 54.9%]
`1,267 Cr	`3,795 Cr
SGNA expenses	SGNA expenses
[Down: 4% QoQ, Up: 5% YoY]	[Up: 4% YoY]
`395 Cr	`1,122 Cr
R&D expenses	R&D expenses
[9.0% of Revenues]	[8.6% of Revenues]
`1,074 Cr	`3,642 Cr
EBITDA	EBITDA
[Down: 25% QoQ; Up: 24% YoY]	[Up: 44% YoY]
`(527 Cr)*	`1,089 Cr
Profit before Tax	Profit before Tax
[Down: 169% QoQ; 191% YoY]	[Down: 34% YoY]

* Excluding intangibles impairment of `1,320 Cr; Profit before tax is `793 Cr

Commenting on the results, Co-Chairman and MD, GV Prasad said "The current quarter performance has been good across all our businesses and we achieved strong EBITDA margins. The profits were impacted due to trigger based impairment charge taken on a few products including gNuvaring. We continue to focus on execution and have made significant progress on quality systems and operational efficiencies".

All amounts in millions, except EPSAll US dollar amounts based on convenience translation rate of I USD = `71.36

Dr. Reddy's Laboratories Limited and Subsidiaries

Consolidated Income Statement

	Particulars			Q3 FY20			Q3 FY19			YoY			Q2 FY20			QoQ
			($)			(Rs.)			($)			(Rs.)			Gr %			($)			(Rs.)			Gr%
	Revenues	614		43,838		540		38,500		14		673		48,009		(9)
	Cost of Revenues	282		20,116		249		17,748		13		286		20,389		(1)
	Gross Profit	332		23,722		291		20,752		14		387		27,620		(14)
	Operating Expenses
	Selling, General & Administrative	178		12,670		169		12,036		5		185		13,217		(4)
	expenses
	Research and Development expenses	55		3,949		51		3,668		8		51		3,662		8
	Impairment of non-current assets	185		13,200		-		-					50		3,560		271
	Other operating (income)	(3)		(228)		(10)		(681)		(67)		(2)		(135)		68
	Results from operating activities	(82)		(5,869)		80		5,729		(202)		103		7,316		(180)
	Net finance (income)	(6)		(419)		0		13					(3)		(231)		81
	Share of (profit) / loss of equity	(2)		(176)		(1)		(89)		98		(2)		(117)		50
	accounted investees
	Profit before income tax	(74)		(5,274)		81		5,805		(191)		107		7,664		(169)
	Income tax expense	6		423		13		953		(56)		(46)		(3,261)		(113)
	Profit for the period	(80)		(5,697)		68		4,852		(217)		153		10,925		(152)
	Diluted Earnings Per Share (EPS)	(0.48)		(34.37)		0.41		29.21		(217)		0.92		65.82		(152)

	Q3
As % to Revenues	FY20
Gross Profit	54.1
SG&A	28.9
R&D	9.0
EBITDA	24.5
PBT*	(12.0)
PAT	(13.0)

*Excluding intangibles impairment Q3 FY20 PBT @ 18.1%

Q3
FY19
53.9
31.3
9.5
22.5
15.1
12.6

Q2
FY20
57.5
34.9
7.6
29.9
16.0
22.8

EBITDA Computation

	Particulars			Q3 FY20				Q3 FY19				Q2 FY20
			($)			(Rs.)				($)			(Rs.)				($)			(Rs.)
	Profit before Income Tax	(74)		(5,274)			81		5,805			107		7,664
	Interest (income) net*	(4)		(274)			(4)		(260)			(3)		(226)
	Depreciation	30		2,130			29		2,073			32		2,306
	Amortization	13		955			14		1,035			14		1,033
	Impairment	185		13,200			-		-			50		3,561
	EBITDA	150		10,737			121		8,652			201		14,338

* Includes income from Investments

Note: Q3 FY20 Financials include an impairment charge of Rs. 13,200 million on some of the Company's products forming part of Global Generics and Proprietary Products segments

Q2 FY20 Financials include Rs. 6,901 million from the out-licensing income, net of expenses related to Neuro products of Proprietary Products

Q2 FY20 Financials include an impairment charge of Rs. 3,561 million on some of the Company's products forming part of Global Generics segment

All amounts in millions, except EPS				All US dollar amounts based on convenience translation rate of I USD = `71.36
					Key Balance Sheet Items
							As on 31stDec,			As on 30thSep			As on 31stDec
		Particulars						2019					2019						2018
							($)			(Rs.)			($)				(Rs.)			($)			(Rs.)
Cash and cash equivalents and other investments		287		20,457		427		30,446			359		25,593
Trade receivables (current & non-current)		646		46,095		591		42,153			523		37,302
Inventories				529		37,746		491		35,033			475		33,911
Property, plant and equipment				739		52,709		743		53,008			776		55,344
Goodwill and Other Intangible assets				432		30,847		621		44,340			690		49,205
Loans and borrowings (current & non-current)		229		16,320		442		31,545			614		43,836
Trade payables				250		17,810		216		15,434			223		15,939
Equity				2,083			1,48,672		2,155		1,53,816			1,902		1,35,708
					Revenue Mix by Segment
					Q3 FY20		Q3 FY19					YoY			Q2 FY20				QoQ
																							Growth
		Particulars			(Rs.)				(Rs.)			Growth %			(Rs.)
														%
		Global Generics	35,927			31,347			15%			32,816					9%
		North America	15,999				14,832			8%			14,265					12%
		Europe	3,093				2,030			52%			2,764						12%
		India	7,636				6,741			13%			7,511						2%
		Emerging Markets	9,199				7,744			19%			8,276						11%
		Pharmaceutical Services and	6,906				5,937			16%			7,107					-3%
		Active Ingredients (PSAI)
		Proprietary Products & Others	1,005				1,216			(18%)			8,086			(88%)
		Total			43,838			38,500			14%				48,009					(9%)

	Q3 FY20 Sales Mix
2%		North America
16%		Europe
	36%	India
21%		Emerging Markets
		PSAI
	7%
17%		Proprietary Products &
		Others

Revenue analysis (Segment wise)

Sales for the quarter is `43.8 billion with a year-on-year growth of 14%. Sequentially, it has declined by 9%. In Q2 FY 20, we had out-licensed 2 neuro products of the proprietary products business and recognized a revenue of `7.2 billion. Adjusted for this, the sequential quarter growth is 7%, and is highest ever quarterly sales from operations, without any one-off item.

Global Generics (GG)

Revenues from GGsegment at `35.9 billion. Year-on-year growth of 15%, primarily driven by Europe, Emerging Markets and India. Sequential growth of 9%, primarily driven by NAG, Europe and EM.

• Revenues fromNorth Americaat `16.0 billion. Year-on-year revenues grew by 8%. Sequential growth of 12%, largely on account of higher volumes in some of our key molecules partly offset by price erosion in some of our key molecules. We launched five new products (Bortezomib injection, Doxercalciferol, Deferasirox dispersable tabs, Deferasirox film coated tabs, Sodium Nitroprusside injection) during the quarter.
  As of 31stDecember 2019, cumulatively 101 generic filings are pending for approval with the USFDA (99 ANDAs and 2 NDAs under 505(b)(2) route). Of these 99 ANDAs, 53 are Para IVs out of which we believe 32 have 'First to File' status.
• Revenues fromEmerging Marketsat `9.2 billion. Year-on-year growth is 19%. Sequential growth is 11%.
• • Revenues fromRussiaat `4.9 billion. Year-on-year growth of 20%. Growth primarily driven by increase in volumes coupled with better realizations in some of the key molecules.
  • Revenues fromother CIS countries and Romaniamarket at `1.8 billion. Year-on-year growth of 26% largely driven by new products and volume traction.
  • Revenues fromRest of World (RoW)territories at `2.5 billion. Year-on-year growth of 12%, primarily driven by new products coupled with volume traction partly offset by price erosions in some of the key molecules.
• Revenues fromIndiaat `7.6 billion. Year-on-year growth of 13%, driven by new products, improved realizations in base business and volume traction. Sequential growth is 2% due to improved realizations and launch of new products.
• Revenues fromEuropeat `3.1 billion. Year-on-year growth of 52%, primarily on account of new products and volume traction in base business partly offset by lower realizations as few key molecules entered tenders. Sequential growth is 12% due to improvement in the sales of base business.

Pharmaceutical Services and Active Ingredients (PSAI)

• Revenues fromPSAIat `6.9 billion. Year-on-year growth of 16% largely driven by increase in volumes of API business. There is a sequential decline of 3% due to lower volumes pick up compared to Q2.

Proprietary Products Segment (PP)

• Revenues from PP at`0.2 billion, as against `0.7 billion in Q3 FY 19 and `7.4 billion in Q2 FY 20, as we had out-licensed our commercialized derma products in Q4 FY 19 and commercialized neuro products in Q2 FY 20.

Income Statement Highlights:

• • Gross profit margin at 54.1% vs. Q3 FY 19 margin of 53.9% and Q2 FY 20 margin of 57.5%
  • • Gross profit margin for GG and PSAI business segments are at 58.2% and 30.0% respectively.
    • Year on year gross profit margins marginally improved on account of new products contribution with better margins and manufacturing leverage offset by higher price erosion in some of the key molecules in the US, Europe and RoW markets.
    • Sequentially there is a decline in margin as during the last quarter we recognized revenue from theout-licencing of PP Neuro products. On a like to like basis, the margins improved by ~260 bps due to manufacturing leverage and business mix.
• SG&A expenses at`12.7 billion, an increase of 5% on a year-on-year basis and decline of 4% sequentially. SG&A as % to sales improved by 240 bps on a year-on-year basis and on a like-to-like basis leverage improved sequentially as well.
• • In December, 2019 there has been a generic launch and an authorized generic launch for the product Nuvaring®, which has led to a considerable erosion in the value of this product for us, and accordingly we have taken an impairment charge of`11.1 billion ($ 156.5 mn). In addition to this, considering the current market dynamics, we have taken an impairment charge of `2.1 billion on the intangibles pertaining to other products. In total, we have taken an impairment of `13.2 billion on the intangible assets for this quarter. In Q2 FY 20, we had an impairment charge of `3.6 billion.
  • R&D expenses at`3.9 billion. As % to Revenues- Q3 FY20: 9.0% | Q2 FY 20: 7.6% | Q3 FY19: 9.5%. Focus continues on building healthy pipeline of products across our markets.
• Other operating income at`228 million compared to `681 million in Q3 FY19. Previous year includes `423 million on account of sale of API business manufacturing unit located at Jeedimetla, Hyderabad.
• Net Finance income at`419 million compared to net finance expense of `13 million in Q3 FY19. The increase is primarily on account of foreign exchange gain in current quarter compared to loss in Q3 FY19.
• Loss before Tax at`5.3 billion, loss is primarily on account of impairment of intangible assets. Excluding impairment, profit before tax is at `7.9 billion.
• The net tax for the quarter is at`0.42 billion.
• Diluted loss per share is at`34.4
• • Capital expenditure is at`1.2 billion.

Earnings Call Details (06:30 pm IST, 08:00 am EST, January 27, 2020)

The Company will host an earnings call to discuss the performance and answer any questions from participants.

Audio conference Participants can dial-in on the numbers below:

Universal Access Number:		+91	22 6280 1219
Secondary number:		+91	22 7115 8120
Local Access number:		[phone]
(Available all over India)
International Toll Free Number USA	1 866 746 2133
	UK	0 808 101 1573
	Singapore	800	101 2045
	Hong Kong	800	964 448
Playback of call:	[phone], [phone]
Conference ID:	58113

Transcript of the event will be available at www.drreddys.com. Playback will be available for a few days.

………………………………………………………………………………………………………………………………………………………..…………………………..…

About Dr. Reddy's:Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

………………………………………………………………………………………………………………………………………………………..…………………………..…

Disclaimer:This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.

The company assumes no obligation to update any information contained herein.